---
title: "Repository-Clinical"
description: "Anything that helps my learning into the topics."
hideBackToTop: false
hidePagination: true
---
[2021_08_NEJM: Empagliflozin in Heart Failure with a Preserved Ejection Fraction](https://www.nejm.org/doi/full/10.1056/NEJMoa2107038)\
Empagliflozin use in HFpE. 

[2022_11_Lancet: Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial](https://doi.org/10.1016/S0140-6736(22)02083-9)\
IV Iron use in HFrEF.

[2005_05_NEJM: Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis](https://www.nejm.org/doi/full/10.1056/NEJMoa050516)\
Infliximab induction.

[2015_04_NEJM: Prednisolone or Pentoxifylline for Alcoholic Hepatitis](https://www.nejm.org/doi/full/10.1056/NEJMoa1412278)\
Pentoxifylline did not improve survival in patients with alcoholic hepatitis.

[2002_07_Gastroenterology: Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: A randomized, controlled, double-blind trial](https://doi.org/10.1053/gast.2002.34230)\
IV Erythromycin before emergency endoscopy improves quality of endoscopy

[2007_08_Clinical_Infectious_Diseases: A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity](https://doi.org/10.1086/519265)\
Vancomycin and Metronidazole equally effective in C.diff infection
 
| Study Name | Author and Year | Type of Study and Sample Size       | Treatment and Duration    | Study Endpoint and Primary Outcome | Results                      |
| ---------- | --------------- | ----------------------------------- | ------------------------- | ---------------------------------- | ---------------------------- |
| Study 1    | Author A (2020) | Randomized Controlled Trial (n=100) | Drug A, 6 months          | Endpoint X, Outcome Y              | Significant improvement in Y |
| Study 2    | Author B (2019) | Cohort Study (n=200)                | Treatment B, 1 year       | Endpoint Z, Outcome W              | No significant change in W   |
| Study 3    | Author C (2021) | Case-Control Study (n=150)          | Intervention C, 3 months  | Endpoint Y, Outcome Z              | Outcome Z improved by 15%    |
| Study 4    | Author D (2018) | Cross-Sectional Study (n=250)       | Lifestyle change, 6 weeks | Endpoint A, Outcome B              | Minor improvement in B       |
| Study 5    | Author E (2022) | Meta-Analysis (n=10 studies)        | Various, Duration varies  | Endpoint C, Outcome D              | Overall positive trend in D  |
